NextCure
NXTC
78 hedge funds and large institutions have $122M invested in NextCure in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 28 closing their positions.
58% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.08M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.76% less ownership
Funds ownership: 5.42% → 4.67% (-0.76%)
15% less funds holding
Funds holding: 92 → 78 (-14)
32% less capital invested
Capital invested by funds: $180M → $122M (-$57.8M)
39% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 33
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.35M |
| 2 |
Millennium Management
New York
|
+$2.67M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.56M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.43M |
| 5 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$8.13M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$5.64M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.5M |
| 4 |
Morgan Stanley
New York
|
-$3.43M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.97M |
NXTC Hedge Fund Activity: Q2 2021 in Review
78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q2 2021, worth a combined $122M — down 32% from $180M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of NXTC and 14 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 20 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $4.35M. The largest seller was BlackRock, cutting an estimated $8.13M.
- 78 institutional investors held NextCure (NXTC) as of Q2 2021, down from 92 in Q1 2021.
- Funds reported $122M of NextCure stock for Q2 2021, down 32% quarter-over-quarter.
- 14 funds opened new NextCure positions in Q2 2021 and 28 closed out, a net change of -14 holders.
- The largest NextCure buyer in Q2 2021 was Federated Hermes, an estimated $4.35M added.
- The largest NextCure seller in Q2 2021 was BlackRock, an estimated $8.13M sold.
Based on aggregated 13F filings for Q2 2021.